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Bisphenol A Impairs Mitochondrial Function in the Liver at 
Doses below the No Observed Adverse Effect Level
Bisphenol A (BPA) has been reported to possess hepatic toxicity. We investigated the 
hypothesis that BPA, below the no observed adverse effect level (NOAEL), can induce 
hepatic damage and mitochondrial dysfunction by increasing oxidative stress in the liver. 
Two doses of BPA, 0.05 and 1.2 mg/kg body weight/day, were administered 
intraperitoneally for 5 days to mice. Both treatments impaired the structure of the hepatic 
mitochondria, although oxygen consumption rate and expression of the respiratory 
complex decreased only at the higher dose. The hepatic levels of malondialdehyde (MDA), 
a naturally occurring product of lipid peroxidation, increased, while the expression of 
glutathione peroxidase 3 (GPx3) decreased, after BPA treatment. The expression levels of 
proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) 
also increased. In HepG2 cells, 10 or 100 nM of BPA also decreased the oxygen 
consumption rate, ATP production, and the mitochondrial membrane potential. In 
conclusion, doses of BPA below the NOAEL induce mitochondrial dysfunction in the liver, 
and this is associated with an increase in oxidative stress and inflammation. 
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INTRODUCTION
Bisphenol A (BPA), a key monomer in the production of poly-
carbonate plastics and epoxy resin, is widely used in a variety of 
products, including baby bottles, food storage containers, and 
dental sealants (1, 2). Trace amount of BPA released from these 
products leads to human exposure. Thus, in humans, BPA is 
detected not only in serum and urine but also in the placenta 
and amniotic fluid (3, 4). 
  The United States (US) Food and Drug Administration (FDA) 
has announced a no observed adverse effect level (NOAEL) of 
5 mg BPA/kg body weight (bw)/day, and the European Food 
Safety Authority (EFSA) and the US Environmental Protection 
Agency (EPA) have derived a tolerable daily intake (TDI), or ref-
erence dose, of 0.05 mg/kg bw/day (5-7) based on rodent stud-
ies (8, 9). However, considering that human exposure is abun-
dant and prolonged, there are controversies about this criteria 
based on single dose exposure in animal studies. Recently, sev-
eral researches have been being carried and these suggest that 
a low dose of BPA below the NOAEL have significant effects 
(10-13).
  The adverse effects of BPA are largely related to its estrogenic 
activity (14, 15), and result in disturbances to reproductive func-
tion (16), steroidogenesis (17), and adipogenesis (18). However, 
BPA has other effects such as inflammatory cytokine (18, 19) 
and an increase of oxidative stress (20-22), which is indepen-
dent of estrogenic activity. 
  The liver is the major organ for the metabolism and detoxifi-
cation of xenobiotics, including BPA (23). Therefore, the liver 
could be largely exposed to BPA, and could be susceptible to 
lower doses, than other organs. In humans, the urinary concen-
tration of BPA was associated with abnormal liver function (24). 
There are some reports that high doses of BPA altered liver 
weights in mice or rats (8, 9) and decreased the viability of rat 
hepatocytes (20). However, it is still unknown whether a low 
dose of BPA, below the NOAEL or TDI, has adverse effects on 
the liver. Therefore, we investigated the effects of doses of BPA 
below the NOAEL on hepatic function, especially focusing on 
oxidative stress and mitochondrial function both in vivo and in 
vitro.Moon MK, et al.  •  Effect of Bisphenol A on Mitochondrial Function
http://jkms.org   645 http://dx.doi.org/10.3346/jkms.2012.27.6.644
MATERIALS AND METHODS
Animals
Specific pathogen-free C57BL/6 male mice at 3 weeks of age 
were purchased from the Orient Co., Ltd. (Seongnam, Korea). 
The mice were acclimatized to the laboratory environment for 
1 week prior to the experiments, and then, divided into 3 groups. 
Mice were injected intraperitoneally with normal saline, 0.05 
mg/kg body weight (bw)/day of BPA (referred to as the lower 
dose), or 1.2 mg/kg bw/day of BPA (referred to as the higher 
dose) every 24 hr for 5 days. The number of mice was 5 for each 
group, and the experiment was repeated at least 3 times from 
2009 to 2010. All mice were housed in conventional plastic cages 
with free access to water and chow diet at 23°C ± 2°C, 60% ± 10% 
humidity, and a 12-hr light/12-hr dark photoperiod. At the end 
of the study, mice were fasted for 8 hr, anesthetized, and then, 
sacrificed.
  To investigate the time-course of effect of BPA, another sepa-
rate animal study was conducted. In this study, mice were in-
jected intraperitoneally with 1.2 mg/kg bw/day of BPA, and sac-
rificed 1, 6, and 24 hr after injection. The number of mice was 5 
for each group, and the experiment was repeated twice.
  All procedures involving the use of laboratory animals were 
in accordance with the Guide for Standard Operation Proce-
dures, and were performed after receiving approval of the insti-
tutional animal care and use committee (IACUC) in the Clinical 
Research Institute, Seoul National University Bundang Hospital 
(IACUC approval No. BA1103-079/021-01).
Cells
HepG2 cells were grown in Roswell Park Memorial Institute 
(RPMI)-1640 medium (Invitrogen, Carlsbad, CA, USA) contain-
ing 10% fetal bovine serum, 10 mM HEPES (pH 7.4), 10.2 mM L-
glutamine, 50 mM sodium pyruvate, 2.5 mM β-mercaptoethanol, 
0.1 mg/mL streptomycin, and 100 U/mL penicillin. All cells were 
incubated at 37°C in a humidified chamber supplemented with 
5% CO2. Cells were treated with 10 nM and 100 nM of BPA for 2, 
6, 12, or 24 hr. 
Materials
BPA (purity  > 99%) was purchased from Sigma (St. Louis, MO, 
USA). BPA was mixed with 30% ethanol and diluted with water 
to the appropriate concentrations for the experiments. 
Liver enzyme and cytokine measurements
Serum aspartate aminotransferase (AST) and alanine transfer-
ase (ALT) were determined by Beckman Coulter AU480 auto-
matic biochemistry analysis system (Brea, CA, USA) with reagent 
kits provided by the manufacturer. IL-6 and TNF-α were mea-
sured using a radioimmunoassay kit (Linco, St. Charles, MO, 
USA), following the protocol provided by the manufacturer. 
Transmission electron microscopy
Liver and pancreas tissues were dissected, cut into small sec-
tions (1 × 1 mm), and immersed in 2.5% glutaraldehyde at 4°C. 
Samples were post fixed in 1% osmium tetroxide in 0.1 M phos-
phate or cacodylate buffer at pH 7.2 for 1.5 hr. Samples were 
then washed with water, dehydrated in an increasing series 
(50%, 60%, 70%, 80%, 90%, and 100%) of ethanol, and immersed 
in propylene oxide (Acros Organics, Morris Plains, NJ, USA) and 
then EPON epoxy resin (Electron Microscopy Polysciences, 
Hatfield, PA, USA). Samples embedded in the epoxy resin were 
put into a capsule and polymerized at 38°C for 12 hr and at 60°C 
for 48 hr. 
  Samples were then cut into 50-μm thick ultrathin slices by 
using an ultramicrotome (RMC MT-XL), and stained with 4% 
uranyl acetate and 4% lead citrate. Structures were examined 
by transmission electron microscopy (15,000 ×  and 50,000 ×  
magnification).
Mitochondrial function assays
High-resolution respirometry was used to measure the oxygen 
consumption rate of the mitochondria of both the liver tissues 
and HepG2 cells. The oxygen consumption rate of the mito-
chondria was measured as described previously (25). Briefly, 
the hepatic mitochondria were isolated by centrifugation in 
MIB buffer, containing 10 mM Tris-HCl pH 7.4, 250 mM sucrose, 
and 1 mM EDTA, and 200 μg of mitochondria was mixed with 
MIRO5 buffer, containing 0.5 mM EGTA, 3 mM MgCl2 • 6H2O, 
60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM 
HEPES, 110 mM sucrose, and 1 g/L BSA. The sample was trans-
ferred to the chamber of an Oxygraph-2K apparatus (Oroboros, 
Innsbruk, Austria). The basal oxygen consumption rate (state 2 
respiration) was recorded after the addition of 20 mM glutamate 
and 8 mM malate as substrates of complex I, and then, state 3 
respiration was assessed by the addition of 2 mM ADP (GMD). 
Cytochrome c (GMcD) was added to assess the integrity of the 
outer mitochondrial membrane. Subsequently, 10 mM succi-
nate (GMcDS), as a substrate of complex II, and 0.5 M carbon-
ylcyanide p-triflouromethoxyphenylhydrazone (FCCP), as an 
uncoupler, were added sequentially. The oxygen consumption 
rate was expressed as picomoles of oxygen consumed/s/mg of 
mitochondrial protein.
  The cellular ATP production and mitochondrial membrane 
potential (MMP) were also measured in the HepG2 cells. Cellu-
lar ATP levels were measured using a luminescence ATP detec-
tion assay kit (PerkinElmer, Waltham, MA, USA). The assay was 
carried out in 96-well plates, according to the manufacturer’s 
instruction. The luminescence was detected on a microplate 
reader (Wallac Victor3V 1420 Multilabel Counter; PerkinElmer) 
as counts per second (CPS). The relative ATP level was calculat-
ed by dividing the CPS of the BPA-treated samples by those of 
the control samples.Moon MK, et al.  •  Effect of Bisphenol A on Mitochondrial Function
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  The MMP was determined by measuring the red fluorescence 
of the cationic carbocyanine dye JC-1 (5, 5´, 6, 6´-tetrachloro-1, 
1´, 3, 3´-tetraethylbenzimidazolylcarbocyanine iodide) (Invitro-
gen). Briefly, 1 × 10
4 cells were loaded on the 96-well plate, 200 μL 
of 2 μM JC-1 was added to the media, and then the plate was 
incubated at 37°C for 2 hr. Following the incubation, the media 
was removed from each well of the plate and washed with phos-
phate-buffered saline (PBS). The fluorescence was measured at 
an excitation wavelength of 485 nm and an emission wavelength 
of 590 nm with a fluorescent microplate reader (Wallac Victor3V 
1420 Multilabel Counter; PerkinElmer). The MMP was expressed 
as the ratio of red fluorescence (590 nm) to green fluorescence 
(485 nm). 
Protein analysis (western blot)
Liver tissue was harvested at the end of the study and subjected 
to immunoblotting analysis. Tissues were homogenized in lysis 
buffer (Cell Signaling Tech., Danvers, MA, USA), and the pro-
tein concentration was determined using a protein assay kit 
(Pierce Biotechnology, Rockford, IL, USA). 
  Protein (12 μg) was mixed with gel loading buffer, containing 
62.5 mM Tris-HCl, 2% sodium dodecyl sulfate (SDS), 5% 2-mer-
captoethanol, 13% glycerol, and 0.013% bromophenol blue, and 
loaded onto a 9% SDS-polyacrylamide electrophoresis gel, which 
was electrophoresed in buffer containing 25 mM Tris-HCl, 250 
mM glycine, and 0.1% SDS. The protein was transferred to a 
polyvinylidene difluoride membrane in buffer containing 25 
mM Tris, 192 mM glycerin, and 20% methanol (pH 8.3) for 1 hr, 
and the membrane was then washed with TBS buffer. Primary 
antibody was diluted with TBS buffer with 5% skim milk and 
incubated with the membrane overnight at 4°C. The primary 
antibodies used were complex I (20 kDa, MitoSciences compa-
ny, Eugene, OR, USA), complex II (32 kDa), complex III (45 kDa), 
complex IV (25 kDa), complex V (55 kDa), interleukin-6 (IL-6) 
(24 kDa, AbCam, Cambridge, MA, USA), tumor necrosis factor-α 
(TNF-α) (17 kDa, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA), catalase (55 kDa, Santa Cruz), glutathione peroxi-
dase 3 (GPx3) (2 kDa, Santa Cruz), and actin (42 kDa, Sigma). 
After washing with TBS buffer, the membrane was re-incubated 
with secondary antibody for 1 hr at room temperature. The sec-
ondary antibodies were anti-rabbit, anti-goat, and anti-mouse 
antibodies.
 
Oxidative stress assays
The thiobarbituric acid reactive substance (TBARS) assay was 
used to measure the oxidative stress in the hepatic tissues or 
HepG2 cells. Tissues or cells were homogenized in 250 μL of 
RIPA buffer (50 mM Tris-HCl, pH 8.0, with 150 mM sodium 
chloride, 1.0% Igepal CA-640 [NP-40], 0.5% sodium deoxycho-
late, and 0.1% sodium dodecyl sulfate) on ice. Samples were 
centrifuged, and the supernatant was stored at -80°C until use. 
Homogenates were assayed in duplicate using a TBARS assay 
kit (Cayman Chemical, Ann Arbor, MI, USA) to determine the 
content of malondialdehyde (MDA). Samples were mixed with 
SDS solution and color reagent, boiled for 1 hr, incubated on ice 
for 10 min, and centrifuged at 1,600 g at 4°C for 10 min. Samples 
were loaded with MDA standards on a 96-well plate, and the 
absorbance at 530-540 nm was read. The TBARS levels were 
calculated from a standard curve of MDA. 
  In HepG2 cells, the intracellular reactive oxygen species (ROS) 
was also measured using the ROS-sensitive fluorescent indica-
tor dihydroethidium (DHE) (Sigma). The cells were incubated 
with 10 mg/L DHE for 30 min at 37°C, and then washed twice 
with PBS. Following this, the cells were treated with BPA (100 
nM), and then, fluorescent microscopy images were obtained.
Statistical analysis
Statistical analysis was performed by non-parametric analysis 
by using the Mann-Whitney and Kruskal-Wallis tests. Statistical 
significance was assumed at P < 0.05.
 
RESULTS
Impairment of mitochondrial structure and function by 
BPA
There were no differences in the weight of the liver or its histol-
ogy (studied by hematoxylin and eosin staining) between the 
control and BPA-treated mice (data not shown). However, the 
hepatic mitochondria in the mice treated with 1.2 mg/kg bw/
day of BPA were much more swollen than those in the control 
mice, as viewed with transmission electron microscopy (Fig. 
1A). The oxygen consumption rates (glutamate + malate + ADP 
[GMD], GMcD + succinate [GMcDS], and carbonylcyanide p-
triflouromethoxyphenylhydrazone [FCCP]) were reduced in the 
hepatic mitochondria in the BPA-treated mice (Fig. 1B), espe-
cially state 3 respiration (GMD), which significantly decreased 
(P = 0.03). The expression of the respiratory complex III and V 
was also reduced in the BPA-treated mice compared to the con-
trol mice (Fig. 1C). 
Acute changes of liver enzymes by BPA
To investigate the possible hepatic toxicity of BPA, we measured 
the liver serum enzymes AST and ALT. Within 24 hr of a single 
injection of 1.2 mg/kg bw/day of BPA, both AST and ALT levels 
significantly increased (P = 0.03 and 0.01, respectively) (Fig. 2). 
However, we could not find any difference after 5 days of treat-
ment (ALT, 60 ± 14 IU/L vs 57 ± 10 IU/L, P > 0.05), although 
serum AST levels showed an increasing tendency in BPA-treated 
mice (30 ± 4 U/L vs 46 ± 20 U/L, P > 0.05). 
Oxidative stress and inflammatory cytokines in the liver
We next investigated the mechanism of mitochondrial dysfunc-Moon MK, et al.  •  Effect of Bisphenol A on Mitochondrial Function
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tion in the liver. Since both oxidative stress and inflammation 
can induce hepatic mitochondrial dysfunction (26), we mea-
sured the hepatic MDA concentrations and the hepatic expres-
sion of IL-6 and TNF-α at 1, 6, and 24 hr after the injection of 1.2 
mg/kg bw/day of BPA. 
  The hepatic concentration of MDA, which is a product of lipid 
peroxidation, was measured as an indicator of oxidative stress. 
After a single injection of BPA, MDA concentrations gradually 
increased over time for 6 hr (P = 0.04) (Fig. 3A), while the he-
patic expression of GPx3, an important antioxidant enzyme, 
decreased over the same period (Fig. 3B). In contrast, the ex-
pression of catalase remained unchanged. Because inflamma-
tory cytokines can induce oxidative stress, we measured the he-
patic expression of IL-6 and TNF-α. IL-6 expression increased 
1 and 6 hr after BPA injection, suggesting a pathogenic role, while 
the expression of TNF-α was unchanged (Fig. 3C). Serum IL-6 
and TNF-α levels showed similar results (P < 0.01, P = 0.02 re-
spectively) (Fig. 3D). 
  Mitochondrial function measured as the oxygen consump-
tion rate significantly decreased 6 hr after BPA treatment (P =  
0.03), but had recovered by 24 hr (Fig. 3E). Therefore, this showed 
that the changes in the levels of inflammatory cytokines and 
oxidative stress over time had a temporal association with he-
patic mitochondrial dysfunction, and we hypothesized that 
BPA induced expression of proinflammatory cytokines, includ-
ing in the liver, which might increase hepatic oxidative stress. 
Under BPA-treated conditions, hepatic antioxidant enzyme lev-
els decreased; thus, hepatocytes could not be protected from 
BPA-induced oxidative stress resulting in mitochondrial dys-
function. To verify this hypothesis in the mice treated for 5 days, 
we measured MDA and found that MDA concentrations were 
elevated (Fig. 4A). Furthermore, the expression level of GPx3 
decreased in the BPA-treated liver (Fig. 4B).
Effect of lower dose of 0.05 mg/kg bw/day BPA on hepatic 
oxidative stress
We demonstrated that 1.2 mg/kg bw/day of BPA, which is lower 
than the NOAEL in mice (5 mg/kg bw/day), increased hepatic 
oxidative stress, and impaired mitochondrial function. There-
fore, we treated mice with a lower dose of 0.05 mg/kg bw/day 
BPA. The electron microscopy findings were not consistent, and 
the morphology of the hepatic mitochondria varied between 
individual mice; the mitochondrial morphology appeared nor-
mal in some mice, but very large and swollen mitochondria 
were frequently observed in others (Fig. 5A). These results sug-
gested that susceptibility to BPA could differ on an individual 
basis. The oxygen consumption rate of hepatic mitochondria 
A1 A2
Fig. 1. Structure and function of hepatic mitochondria in the mice treated with 1.2 
mg/kg bw/day of BPA for 5 days. (A) Morphology of hepatic mitochondria by trans-
mission electron microscopy (150,000 × magnification). Control mice (A1) and BPA-
treated mice (A2). Normal mitochondria (arrows) and swollen mitochondria (arrow-
heads). (B) Oxygen consumption rate of hepatic mitochondria. GMD, glutamate + 
malate + ADP; GMcD, GMD + cytochrome c; GMcDS, GMcD + succinate; FCCP, un-
coupler (*P < 0.05 compared to control). (C) The respiratory complex I-V of hepatic 
mitochondria.
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showed no difference between 0.05 mg/kg bw/day BPA-treated 
mice and controls, but variations were observed between the 
individuals (Fig. 5B). MDA concentrations representing oxida-
tive stress also increased compared to the controls, even in the 
mice treated with the lower dose of BPA, although this apparent 
difference was not statistically significant (Fig. 5C). GPx3 expres-
sion level also decreased in the mice treated with lower dose of 
BPA (Fig. 5D). Our results suggested that even the “tolerable” or 
“acceptable” lower dose of BPA could also induce hepatic oxi-
dative stress and mitochondrial dysfunction, depending on in-
dividual susceptibility. 
Effect of BPA on mitochondrial function in HepG2 cells
To confirm the effects of BPA on hepatic mitochondria in vitro, 
HepG2 cells were treated with 2 different concentrations of BPA 
(10 nM and 100 nM). Treatment of HepG2 cells with BPA for 2 
hr lead to a deteriorated mitochondrial architecture (Fig. 6A), 
and this was more severe in the 100 nM-treated mice than the 
10 nM-treated HepG2 cell. Not only the morphology but also the 
function of the mitochondria was impaired by BPA treatment; 
oxygen consumption rates were reduced according to the dose 
(Fig. 6B). These results were replicable between 3 separate ex-
periments. We also measured other parameters of mitochon-
drial function and observed the same results; ATP consump-
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Fig. 5. Structure and function of hepatic mitochondria in the mice treated with BPA (0.05 mg/kg bw/day) for 5 days. (A) Morphology of hepatic mitochondria by transmission 
electron microscopy (500,000 × magnification). Control (A1) and BPA-treated mice (A2, A3). Normal mitochondria (arrows) and swollen and cristae-disrupted mitochondria 
(arrowhead). (B) Oxygen consumption rate of hepatic mitochondria. GMD, glutamate + malate + ADP; GMcD, GMD + cytochrome c; GMcDS, GMcD + succinate; FCCP, uncou-
pler. (C) MDA concentrations in the liver. (D) Catalase and GPx3 in the liver.
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tion (Fig. 6C) and MMP (Fig. 6D) were reduced after BPA treat-
ment. To exclude the possibility that cell death caused the mi-
tochondrial dysfunction, a cell viability assay using 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
was performed, and no cell death was observed (data not shown). 
To confirm the increase of oxidative stress by BPA in hepato-
cytes, we measured the MDA concentrations (Fig. 7A) and DHE 
activities (Fig. 7B), and BPA increased both of them. 
 
DISCUSSION
The present study demonstrated that a low dose of BPA, below 
the NOAEL or TDI (the so-called “tolerable” or “acceptable” 
dose), induces mitochondrial dysfunction and structural chang-
es in the mouse liver. BPA increased hepatic oxidative stress 
and proinflammatory cytokines, and decreased antioxidant 
enzyme expression both in vivo and in vitro. All these findings 
suggest that a low dose of BPA can also induce hepatic dysfunc-
tion. 
  The strength of this study is to demonstrate that BPA below 
the permissible limit induces mitochondrial dysfunction and 
structural changes in the liver in vivo. Only in vitro data have 
been reported that BPA inhibits mitochondrial function (20). 
  Recently, the oxidative stress was proposed as another ad-
verse cellular effect of BPA in the liver (21). BPA increased the 
generation of ROS and induced cellular apoptosis in hepato-
cytes (22). Oxidative stress can induce mitochondrial damage, 
and damaged mitochondria can generate more ROS. Mitochon-
dria are vulnerable to ROS due to impairment of the antioxi-
dant and DNA repair enzyme systems (27). Accumulation of 
oxidative damage in the mitochondria induces mitochondrial 
dysfunction, mitochondrial DNA depletion, and cell apoptosis 
(26). In this study, BPA increased ROS production, as assessed 
by the measurement of MDA concentration. An increase in ROS 
was observed even 1 hr after BPA administration. Although mi-
tochondrial dysfunction was not observed, a very low dose of 
BPA, i.e., 0.05 mg/kg bw/day, also increased ROS and decreased 
antioxidant enzymes. Although further studies are required to 
clarify the cause and effect relationship, it is suggested that oxi-
dative stress might be the possible mechanism of this BPA-in-
duced mitochondrial dysfunction. 
  In this study, an increase in the levels of IL-6 and TNF-α was 
observed following BPA treatment. Although ROS can increase 
proinflammatory cytokines (28), proinflammatory cytokines 
themselves can induce oxidative stress (29). We showed that 
the expression of IL-6 increased 1 and 6 hr after BPA injection, 
and serum MDA concentrations gradually increased over time 
for 24 hr. These results suggested that IL-6 might play a patho-
genic role in BPA-induced ROS generation and mitochondrial 
dysfunction. 
  The cell has various defense mechanisms against oxidative 
stress, including scavenging enzyme systems such as catalase 
and GPx3. In this study, BPA reduced GPx3 expression consis-
tent with the previous studies that reported the reduction of 
catalase and GPx activities in the liver and kidney of male ICR 
mice (30) and the sperm of Wistar rats (31). It has been suggest-
ed that BPA exposure produces ROS by inhibiting antioxidant 
enzymes, or that antioxidant enzymes are depleted because of 
ROS production.
  In this study, a single BPA injection acutely increased liver 
enzymes, although the levels of liver enzymes upon treatment 
had a tendency to be similar to those of the control after the 
successive BPA injections for 5 days. We can postulate that BPA 
may induce hepatocyte damage, but there are abundant mech-
anisms to compensate for this. Therefore, the hepatotoxic effects 
of BPA could be counteracted, and this may be the reason why 
the previously elevated hepatic enzyme levels were again re-
duced after 5 days of treatment in our study, although we did 
not examine the possible compensatory mechanism.
  In this study, we injected BPA intraperitoneally, while human 
is usually exposed to BPA via the oral route. This may represent 
Fig. 7. Oxidative stress in HepG2 cells treated with 100 nM BPA. (A) MDA concentra-
tions determined by a TBARS assay kit. (B) Fluorescence after the ROS-sensitive indi-
cator DHE staining. Control (B1), 2 hr (B2), 6 hr (B3), and 24 hr (B4) after the treat-
ment of 100 nM BPA. 
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a limitation of this study, because the route of administration 
can change the BPA bioavailability and metabolism (32). How-
ever, even after considering pharmacokinetics of BPA, doses of 
BPA, which we injected intraperitoneally in this experiment, 
may be equated to about 0.15 mg/kg/day and 4 mg/kg/day for 
the oral administration and these are below the NOAEL.
  In conclusion, a low dose of BPA induces mitochondrial dys-
function in the liver, and this is associated with an increase in 
oxidative stress and inflammation. 
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